Literature DB >> 28651937

Postnatal steroids in extreme preterm infants: Intra-tracheal instillation using surfactant as a vehicle.

L Boel1, S Banerjee2, M Chakraborty3.   

Abstract

Chronic Lung Disease (CLD) is a common respiratory morbidity in survivors following extreme preterm birth, and is associated with adverse neurodevelopment in the long term. Besides demographics, multiple risk factors are implicated in the pathogenesis of CLD. However, early lung inflammation appears to be the common pathway that leads to the pathological and clinical changes observed in CLD. Postnatal use of systemic steroids has been successful in reducing the incidence of CLD but resulted in unacceptable adverse neurodevelopmental outcomes. The efficacy of inhaled steroids is not yet established. We review the evidence of tracheal instillation of steroids using surfactant as a lipid vehicle, including published data on drug distribution, in vitro physical studies, and clinical trials in animals and human infants.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Budesonide; Chronic Lung Disease; Inflammation; Steroids; Surfactant

Mesh:

Substances:

Year:  2017        PMID: 28651937     DOI: 10.1016/j.prrv.2017.05.002

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  3 in total

Review 1.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

2.  Surfactant and budesonide for respiratory distress syndrome: an observational study.

Authors:  T Brett Kothe; Farouk H Sadiq; Nikki Burleyson; Howard L Williams; Connie Anderson; Noah H Hillman
Journal:  Pediatr Res       Date:  2019-11-12       Impact factor: 3.756

3.  Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo.

Authors:  Brandon Baer; Lynda McCaig; Cory Yamashita; Ruud Veldhuizen
Journal:  Lung       Date:  2020-10-26       Impact factor: 2.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.